Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp., a clinical-stage company specializing in immunotherapy, is set to present new preclinical data on their MDNA209 and MDNA113 platforms at the Promise of Interleukin-2 Therapy Conference in Paris. The data highlight potential treatments for autoimmune, graft-versus-host diseases, and cancer therapy enhancements by targeting and activating bifunctional anti-PD1-IL-2 Superkine.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
